Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma.

Ann Surg Oncol 2018 Sep 3;25(9):2756-2766. Epub 2018 Jul 3.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA.

Objective: The aim of this study was to examine the significance of lymphovascular space invasion (LVSI) with a sarcomatous component on the tumor characteristics and clinical outcomes of women with uterine carcinosarcoma (UCS).

Methods: This was a secondary analysis of a prior multicenter retrospective study that examined women with stage I-IV UCS who underwent primary hysterectomy. Archived histopathology slides were reviewed and LVSI was scored as follows: LVSI with a carcinomatous component alone (LVSI-carcinoma; n = 375, 76.8%) or LVSI containing a sarcomatous component with or without a carcinomatous component (LVSI-sarcoma; n = 113, 23.2%). Qualitative metrics of LVSI were correlated to clinicopathological factors and survival outcome.

Results: Tumors in the LVSI-sarcoma group were more likely to have sarcoma dominance (82.1 vs. 26.4%) heterologous sarcomatous component (51.3 vs. 37.9%), low-grade carcinoma (42.5 vs. 22.4%), and large tumor size (81.0 vs. 70.2%) in the primary tumor site compared with tumors in the LVSI-carcinoma group (all p < 0.05). On multivariate analysis, LVSI-sarcoma was independently associated with decreased progression-free survival (5-year rates: 34.9 vs. 40.8%, adjusted hazard ratio [HR] 1.84, 95% confidence interval [CI] 1.36-2.50, p < 0.001), and cause-specific survival (5-year rates: 41.8 vs. 55.9%, adjusted HR 1.95, 95% CI 1.39-2.75, p < 0.001) compared with LVSI-carcinoma. Postoperative radiotherapy for women with LVSI-sarcoma had a higher reduction rate of recurrence/progression of disease (54% reduction, p = 0.04) compared with postoperative radiotherapy for women with LVSI-carcinoma (26% reduction, p = 0.08).

Conclusion: In UCS, the presence of a sarcomatous component in LVSI is particularly prevalent when a tumor has sarcoma dominance. Our study suggests that LVSI containing a sarcomatous component may be a predictor of decreased survival for women with UCS.

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-018-6547-xDOI Listing
September 2018
22 Reads

Publication Analysis

Top Keywords

sarcomatous component
16
space invasion
8
uterine carcinosarcoma
8
carcinomatous component
8
lymphovascular space
8
significance lymphovascular
8
lvsi sarcomatous
8
component
6
lvsi
5
lvsi-sarcoma group
4
underwent primary
4
group sarcoma
4
ucs underwent
4
primary hysterectomy
4
hysterectomy archived
4
outcomeresults tumors
4
archived histopathology
4
tumors lvsi-sarcoma
4
sarcoma dominance
4
i-iv ucs
4

References

(Supplied by CrossRef)

LA Cantrell et al.
Gynecol Oncol 2015

K Matsuo et al.
J Gynecol Oncol 2018

K Matsuo et al.
Ann Oncol 2016

P Morice et al.
Ann Oncol 2003

LD Roman et al.
Gynecol Oncol 1998

MR Chernofsky et al.
Gynecol Oncol 2006

FJ Pol et al.
Gynecol Oncol 2015

T Bosse et al.
Eur J Cancer 2015

K Matsuo et al.
J Surg Oncol 2015

SR Guntupalli et al.
Gynecol Oncol 2012

K Matsuo et al.
Gynecol Oncol 2013

Similar Publications